What is William Blair’s Estimate for KYTX FY2025 Earnings?

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – Analysts at William Blair lifted their FY2025 earnings per share estimates for Kyverna Therapeutics in a report issued on Thursday, November 13th. William Blair analyst S. Corwin now forecasts that the company will earn ($3.74) per share for the year, up from their previous forecast of ($4.04). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.29) per share. William Blair also issued estimates for Kyverna Therapeutics’ Q4 2025 earnings at ($0.88) EPS, Q1 2026 earnings at ($0.92) EPS, Q2 2026 earnings at ($0.86) EPS, Q3 2026 earnings at ($0.89) EPS, Q4 2026 earnings at ($0.92) EPS and FY2026 earnings at ($3.60) EPS.

Other analysts also recently issued research reports about the company. Wells Fargo & Company lifted their target price on Kyverna Therapeutics from $27.00 to $31.00 and gave the company an “overweight” rating in a research report on Wednesday, October 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kyverna Therapeutics in a research note on Tuesday, November 11th. Finally, HC Wainwright upped their price target on shares of Kyverna Therapeutics from $10.00 to $20.00 and gave the company a “buy” rating in a research note on Monday, October 27th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $23.67.

Kyverna Therapeutics Stock Up 6.2%

Kyverna Therapeutics stock opened at $6.88 on Monday. The company has a 50 day moving average of $6.21 and a 200-day moving average of $4.24. Kyverna Therapeutics has a twelve month low of $1.78 and a twelve month high of $8.45. The stock has a market capitalization of $301.34 million, a PE ratio of -1.84 and a beta of 3.78.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.12.

Hedge Funds Weigh In On Kyverna Therapeutics

Several institutional investors have recently added to or reduced their stakes in KYTX. Two Sigma Investments LP boosted its stake in Kyverna Therapeutics by 9.8% during the third quarter. Two Sigma Investments LP now owns 132,451 shares of the company’s stock worth $795,000 after acquiring an additional 11,867 shares in the last quarter. Bridgeway Capital Management LLC grew its stake in shares of Kyverna Therapeutics by 178.1% in the 3rd quarter. Bridgeway Capital Management LLC now owns 174,900 shares of the company’s stock worth $1,049,000 after acquiring an additional 112,000 shares in the last quarter. UBS Group AG increased its stake in Kyverna Therapeutics by 60.4% in the 3rd quarter. UBS Group AG now owns 157,422 shares of the company’s stock valued at $945,000 after buying an additional 59,264 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in Kyverna Therapeutics by 667.8% during the third quarter. BNP Paribas Financial Markets now owns 34,022 shares of the company’s stock worth $204,000 after acquiring an additional 29,591 shares during the period. Finally, Jefferies Financial Group Inc. bought a new position in Kyverna Therapeutics during the third quarter valued at about $98,000. 18.08% of the stock is owned by institutional investors and hedge funds.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.